Who we are
DIPG/DMG Center lead
Sabine Mueller, MD Ph.D. MAS serves as the Head of the Clinical Program of the DIPG/DMG . She also leads the Pediatric Brain Tumor Program at UCSF and the Pacific Pediatric Neuro-Oncology Consortium (www.pnoc.us)
Javad Nazarian, Prof. Ph.D. serves as the Head of the Translational Program of the DIPG/DMG Center Zurich
Dr. Stephanie Mathes, contributes to the DIPG/DMG Center Zurich at as project manager. Her main focus is to obtain regulatory approval for clinical trial opening and management of the program.
Dr. Nicolas Gerber is a pediatric neuro-oncologist and head of the Early Phase Clinical Trials Unit of the Department of Pediatric Oncology at the University Children’s Hospital of Zürich. He is PI of PNOC trials.
Prof Dr. Ana Guerreiro Stücklin, PhD is a pediatric neuro-oncologist and physician scientist at the University Children’s Hospital in Zurich, and will act as Co-PI for PNOC trials.
Dr. med. Annette Weiser, Clinical and Research Fellow Neurooncology/Oncology.
Marion Rizo-Oberholzer is study nurse at the DIPG/DMG Center Zurich and takes care of our patients and families.
Sabine Holzapfel is study nurse at the DIPG/DMG Center Zurich and takes care of our patients and families.
Prof. Dr. Michael Grotzer is the Full Professor of Pediatrics at the Medical Faculty of the University of Zurich and the Director of the Medical Clinic as well as the Medical Director at the University Children’s Hospital Zurich. Professor Grotzer is the head of Neuro Oncology where the center is embedded.
Prof. Dr. Niklaus Krayenbühl is the Head of Pediatric Neurosurgery at University Children’s Hospital of Zürich and Senior Neurosurgeon at the Department of Neurosurgery, University Hospital of Zürich.
Sandra Laternser, MSc in Life Sciences is a research associate in Dr. Nazarian’s lab. She is working at the interface of clinic and research lab and investigating biomarkers of target drugs.
Bettina Kritzer, MSc in Life Sciences, is a research associate in Dr. Nazarian’s lab. She is working at the interface of clinic and research with a focus on cell characterization, drug screening and investigation on new treatment opportunities for DIPG patients.
Antonela Petrović, PhD in Medicinal Chemistry with research background in Molecular Neurobiology. She is working on new combinatorial therapeutic approaches in DMGs with a research focus on targeting the PI3K pathway.
Solène Fernandez, Ph. D in Life Sciences. She is working on implementation of CRISPR-Cas9 screening in order to investigating new therapeutic targets identification and resistance biomarkers of target drugs.
David Bamert, MSc in Biomedicine is a research technician in Dr. Nazarian’s lab. He is working at the interface of clinic and research lab and investigates emerging technologies to find new treatment possibilities.
Ludovica Ciani is a PhD student in Javad Nazarian’s Lab. She is working on the identification of new therapeutic targets involved in DMG tumorigenesis and dictating cell stemness.